Bio-Rad Laboratories, Inc. (BIO)
$
304.61
-14.86 (-4.88%)
Key metrics
Financial statements
Free cash flow per share
12.7642
Market cap
7.6 Billion
Price to sales ratio
2.9708
Debt to equity
0.1973
Current ratio
5.1213
Income quality
-4.5001
Average inventory
794.5 Million
ROE
0.0458
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Bio-Rad Laboratories, Inc. manufactures and distributes a comprehensive array of life science research and clinical diagnostic products across various regions, including the United States, Europe, Asia, Canada, and Latin America. Operating through its Life Science and Clinical Diagnostics segments, the Life Science segment is dedicated to the development, manufacturing, and marketing of reagents, apparatus, and laboratory instruments utilized in diverse research techniques, biopharmaceutical production processes, and food testing regimes. It strategically focuses on selected areas within the life sciences market, such as proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves a wide range of clients, including universities, medical schools, industrial research organizations, governmental agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. On the other hand, the Clinical Diagnostics segment specializes in designing, manufacturing, and supporting test systems, informatics systems, test kits, and specialized quality controls tailored for clinical laboratories within the diagnostics market. It offers reagents, instruments, and software that cater to specific niches in the in vitro diagnostics test market, selling these products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Additionally, the company provides products and systems aimed at separating complex chemical and biological materials, as well as identifying, analyzing, and purifying components. Bio-Rad Laboratories, Inc. utilizes a direct sales force supplemented by distributors, agents, brokers, and resellers to market its products. Established in 1952, the company is headquartered in Hercules, California. The net total of other income and expenses is -$2,611,500,000.00 reflecting non-core financial activities, while the cost of revenue for the company is $1,187,600,000.00 showcasing its production and operational expenses. Furthermore, the weighted average number of diluted shares outstanding is 28,214,000.00 reflecting potential dilution effects, and the weighted average number of shares outstanding is 28,214,000.00 highlighting the company's shareholder base. The EBITDA ratio is -0.83 underscoring the company's operational efficiency. Currently, the stock is priced at $284.07 positioning it in the higher-end market. However, it has a low average trading volume of 254,421.00 indicating lower market activity. With a mid-range market capitalization of $8,243,502,947.00 the company is viewed as a steady performer. Bio-Rad is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth through its advanced research and diagnostic solutions.
Is Bio-Rad Laboratories, Inc. (BIO) a good investment?
Investing in Bio-Rad Laboratories, Inc. (BIO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Bio-Rad Laboratories, Inc. (BIO)'s stock forecast?
Analysts predict Bio-Rad Laboratories, Inc. stock to fluctuate between $211.43 (low) and $387.99 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Bio-Rad Laboratories, Inc.'s market capitalization?
As of 2025-10-30, Bio-Rad Laboratories, Inc.'s market cap is $8,243,502,947, based on 27,062,483 outstanding shares.
How does Bio-Rad Laboratories, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Bio-Rad Laboratories, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Bio-Rad Laboratories, Inc. (BIO) stock?
To buy Bio-Rad Laboratories, Inc. (BIO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BIO. Place an order (Market, Limit, etc.).
What is the best time to invest in Bio-Rad Laboratories, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Bio-Rad Laboratories, Inc. stock ever split?
Bio-Rad Laboratories, Inc.'s last stock split was 2:1 on 2002-03-08.
How did Bio-Rad Laboratories, Inc. perform in the last earnings report?
Revenue: $2,566,500,000 | EPS: -$65.36 | Growth: 199.54%.
Where can I find Bio-Rad Laboratories, Inc.'s investor relations reports?
Visit https://www.bio-rad.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Bio-Rad Laboratories, Inc.?
You can explore historical data from here
What is the all-time high and low for Bio-Rad Laboratories, Inc. stock?
All-time high: $832.70 (2021-09-02) | All-time low: $211.43 (2025-06-03).
What are the key trends affecting Bio-Rad Laboratories, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
fool.com
The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low.
seekingalpha.com
Bio-Rad Laboratories, Inc. ( BIO ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Yong Chung - Vice President of Investor Relations Jonathan DiVincenzo - President & COO Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chairman & CEO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Daniel Leonard - UBS Investment Bank, Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Nephron Research LLC Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
globenewswire.com
BKYI: BIO-key International and IT2Trust Partner to Strengthen IAM and Biometric Security Across the Nordic Region of Denmark, Sweden, Norway and Finland.
businesswire.com
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2025 on Wednesday, October 29, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside th.
globenewswire.com
BIO-key Showcases Next-Gen Identity & Biometric Authentication Solutions at Premier Tech and Cybersecurity Events: GITEX 2025 (Dubai) & 19ENISE (Spain).
businesswire.com
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 89bio, Inc. (NasdaqGM: ETNB) to Roche Holding AG (OTC: RHHBY). Under the terms of the proposed transaction, shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $6.00 per sh.
globenewswire.com
PUNE, India, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Biorad Medisys, an Indian medical device manufacturer with a global footprint, has announced its entry into the US market with the launch of its subsidiary Medtimo Inc. The move comes post Biorad Medisys' completion of acquisition of business assets from ReShape Lifesciences, a weight loss and metabolic health solutions, and its official rebranding to Medtimo Inc. The investment is in line with Biorad Medisys' intention of seeking growth in regulated markets by expanding its portfolio, enhancing its global reach and curating a sharpened product strategy.
seekingalpha.com
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chairman & CEO Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst Good afternoon. Welcome to the Wells Fargo Healthcare Conference.
zacks.com
BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.
globenewswire.com
BKYI: BIO-key Q2'25 Revenue Rose 49% Driven by Increases Across All Three Segments; Launches “BIO-key CyberDefense Initiative.” Investor Call 10am ET today
See all news
